Chikungunya vaccines in development
M Schwameis, N Buchtele, PP Wadowski… - Human vaccines & …, 2016 - Taylor & Francis
M Schwameis, N Buchtele, PP Wadowski, C Schoergenhofer, B Jilma
Human vaccines & immunotherapeutics, 2016•Taylor & FrancisChikungunya virus has become a global health threat, spreading to the industrial world of
Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late
1960s much effort has been put into the development of a vaccine, and several
heterogeneous strategies have already been explored. Only two candidates have recently
qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and
a recombinant live attenuated measles virus-vectored vaccine. This review focuses on the …
Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late
1960s much effort has been put into the development of a vaccine, and several
heterogeneous strategies have already been explored. Only two candidates have recently
qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and
a recombinant live attenuated measles virus-vectored vaccine. This review focuses on the …
Abstract
Chikungunya virus has become a global health threat, spreading to the industrial world of Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, and several heterogeneous strategies have already been explored. Only two candidates have recently qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and a recombinant live attenuated measles virus-vectored vaccine.
This review focuses on the current status of vaccine development against chikungunya virus in humans and discusses the diversity of immunization strategies, results of recent human trials and promising vaccine candidates.
Taylor & Francis Online